- Home
- ATOS vs IKT Comparison
ATOS vs IKT Comparison
Compare ATOS & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATOS
- IKT
- Stock Information
- Founded
- ATOS 2009
- IKT 2008
- Country
- ATOS United States
- IKT United States
- Employees
- ATOS N/A
- IKT N/A
- Industry
- ATOS Biotechnology: Pharmaceutical Preparations
- IKT Biotechnology: Pharmaceutical Preparations
- Sector
- ATOS Health Care
- IKT Health Care
- Exchange
- ATOS Nasdaq
- IKT Nasdaq
- Market Cap
- ATOS 106.9M
- IKT 111.8M
- IPO Year
- ATOS 2012
- IKT 2020
- Fundamental
- Price
- ATOS $0.77
- IKT $1.52
- Analyst Decision
- ATOS Strong Buy
- IKT Hold
- Analyst Count
- ATOS 3
- IKT 1
- Target Price
- ATOS $6.25
- IKT N/A
- AVG Volume (30 Days)
- ATOS 539.9K
- IKT 256.6K
- Earning Date
- ATOS 11-12-2025
- IKT 11-14-2025
- Dividend Yield
- ATOS N/A
- IKT N/A
- EPS Growth
- ATOS N/A
- IKT N/A
- EPS
- ATOS N/A
- IKT N/A
- Revenue
- ATOS N/A
- IKT N/A
- Revenue This Year
- ATOS N/A
- IKT N/A
- Revenue Next Year
- ATOS N/A
- IKT N/A
- P/E Ratio
- ATOS N/A
- IKT N/A
- Revenue Growth
- ATOS N/A
- IKT N/A
- 52 Week Low
- ATOS $0.55
- IKT $1.33
- 52 Week High
- ATOS $1.36
- IKT $4.20
- Technical
- Relative Strength Index (RSI)
- ATOS 34.80
- IKT 45.06
- Support Level
- ATOS $0.77
- IKT $1.50
- Resistance Level
- ATOS $0.85
- IKT $1.65
- Average True Range (ATR)
- ATOS 0.05
- IKT 0.13
- MACD
- ATOS -0.01
- IKT -0.00
- Stochastic Oscillator
- ATOS 18.62
- IKT 34.85
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.